Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Concord Medical Services Holdings(CCM)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CCM
09/24/2026: CCM (1-star) is currently NOT-A-BUY. Pass it for now.
Concord Medical Services Holdings is a healthcare provider operating radiotherapy and diagnostic imaging centers, as well as specialty cancer hospitals in China. The company's main strength lies in its established network and focus on high-demand oncology services, which benefit from an aging population. Its primary growth story revolves around the development of specialized cancer hospitals and proton therapy, though this shift requires significant capital. Key risks include intense competition from public hospitals, strict Chinese healthcare regulations, and reliance on favorable reimbursement policies. The stock is best suited for growth-oriented investors with a high tolerance for volatility and geopolitical risk, who should monitor policy updates and capital expenditure efficiency.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The company faces significant structural and market-related headwinds that limit predictable growth. |
| Momentum investor | Weak fit | The stock has historically exhibited low momentum and high volatility. |
| Value investor | Mixed fit | While the market cap is low, the complex asset base makes valuation difficult to assess. |
| Dividend investor | Weak fit | The company does not provide a dividend yield. |
| Low-risk investor | Weak fit | The regulatory and execution risks in the Chinese healthcare market make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to sharp price fluctuations driven by sentiment on Chinese ADRs. |
| Valuation risk | Medium / high | Determining fair value is difficult given the complexity of the asset-heavy business model. |
| Competition risk (Public Hospital dominance) | High | Public hospitals remain the dominant provider, limiting private sector expansion. |
| Business quality | Medium | The company manages critical medical infrastructure but faces structural profitability constraints. |
| Dividend income | Low / none | No income component exists for investors. |
| Execution risk | High | Successfully managing new specialty hospitals is capital-intensive and operationally difficult. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -82.72% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/24/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.72M USD | Price to earnings Ratio - | 1Y Target Price 1.2 |
Price to earnings Ratio - | 1Y Target Price 1.2 | ||
Volume (30-day avg) 66.7K shares | Beta -0.94 | 52 Weeks Range 3.18 - 6.98 | Updated Date 09/24/2026 |
52 Weeks Range 3.18 - 6.98 | Updated Date 09/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.3 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Radiotherapy and Imaging | Leasing and managing equipment in hospitals. | The core legacy business providing steady, though slow-growth, service income. |
| Specialty Hospitals | Patient services at company-owned cancer hospitals. | The primary growth driver that requires heavy spending to scale. |
| China Operations | Healthcare delivery across Chinese provinces. | Success is entirely dependent on the Chinese regulatory and healthcare environment. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 11.3 | Enterprise Value 514.53M | Price to Sales(TTM) 0.04 |
Enterprise Value 514.53M | Price to Sales(TTM) 0.04 | ||
Enterprise Value to Revenue 7.48 | Enterprise Value to EBITDA -0.96 | Shares Outstanding 2.82M | Shares Floating 1.38M |
Shares Outstanding 2.82M | Shares Floating 1.38M | ||
Percent Insiders 25.65 | Percent Institutions 1.28 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Concord Medical Services Holdings
Exchange NYSE | Headquarters - | ||
IPO Launch date 2009-12-11 | Chairman & CEO Dr. Jianyu Yang | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 610 | Website https://www.concordmedical.com |
Full time employees 610 | Website https://www.concordmedical.com | ||
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, and helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.